Director/PDMR Shareholding

Report this content

19 February 2020 07:00 GMT

 

 

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

 

AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £73.13 per Share.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

 

1   Details of the person discharging managerial responsibilities / person closely associated  
a)   Name     Michel Demaré
2   Reason for the notification  
a)   Position/status     Non-Executive Director
b)   Initial notification /Amendment     Initial notification
3   Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor  
a)   Name     AstraZeneca PLC
b)   LEI     PY6ZZQWO2IZFZC3IOL08
4   Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted    
a)   Description of the financial instrument, type of instrument   Identification code     Ordinary Shares of US$0.25 each in AstraZeneca PLC     GB0009895292  
b)   Nature of the transaction     Share purchase
c)   Price(s) and volume(s)      
Price(s)   Volume(s)
GB£73.13 700
   
d)   Aggregated information     - Aggregated volume     - Price     Not applicable - single transaction  
e)   Date of the transaction     17 February 2020
f)   Place of the transaction     XLON

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 

Media Relations    
Gonzalo Viña   +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
     
Investor Relations    
Thomas Kudsk Larsen   +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (cardiovascular; metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (respiratory; renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free   +1 866 381 72 77


Adrian Kemp
Company Secretary
AstraZeneca PLC


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Subscribe

Documents & Links